While future studies are required to assess the relationship between MAN2B1 subgroups and ADA development, this analysis demonstrates that ADAs have a limited effect on the clinical benefit of VA in patients with AM regardless of the MAN2B1 subgroup and, as such, provides meaningful insight into the disease management of AM in both pediatric and adult patients. This evidence concerns the gene ADA and acute myeloblastic leukemia with maturation.